drugset / Trial / NCT03964493
TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate safety, tolerability, pharmacokinetic characteristics and efficacy of TNP-2092 in adults with ABSSSI suspected or confirmed to be caused by gram-positive pathogens.
Timeline
- Start
- 2019-04-20
- Primary completion
- 2020-09-28
- Completion
- 2020-09-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RIFAQUIZINONE | Small molecule | 300 mg | Intravenous |
| Comparator | Vancomycin | Other / unclassified | 1000 mg | Intravenous |